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Of similar size to a pacemaker, implantable loop recorders (ILRs) are implanted 
subcutaneously in the left precordial region. The ILRs are equipped with a memory 
loop and, once activated by the patient by means of a magnet, record a 1-lead elec-
trocardiographic trace, both retrospectively and prospectively, for several minutes. 
ILRs have a monitoring capability of up to 36 months and are explanted once the 
diagnosis has been made or the battery has run down. The current indication of ILRs 
as diagnostic tools is rapresented by the evaluation of transitory symptoms of possible 
arrhythmic origin, such as syncope and palpitations. Moreover, the theoretical capabil-
ity of the new generation ILRs to record any kind of arrhythmic events automatically 
(from atrial fibrillation, to atrial flutter/tachycardia, from ventricular tachycardia to 
bradyarrhytmic events) suggests the possibility to use these devices also in the long-
term evaluation of the total (symptomatic and asymptomatic) arrhythmic burden of 
patients at risk of arrhythmic events. 
D I A G N O s t I c  E v A L U A t I O N  O f  t r A N s I t O r Y  s Y m P t O m s 
O f  P O s s I b L E  A r r H Y t H m I c  O r I G I N
Initial evaluation. In patients with transitory symptoms of possible arrhythmic 
origin, it is essential to ascertain whether there is a structural heart disease and/or 
heart disease at risk of arrhythmias, and to obtain an  electrocardiographic recording 
during symptoms. Therefore, the initial evaluation will involve thorough clinical history, 
careful objective examination and 12-lead ECG (1,2). In some particular situations, it 
may be useful to perform blood chemistry examinations, such as hemochrome, elec-
trolytes, blood glucose, and thyroid function tests (3). Effort stress testing is indicated 
in case of symptoms associated with physical effort, while tilt testing is indicated in 
patients without heart disease suffering from recurrent syncope of unexplained origin. 
The need for further investigations (echocardiogram, coronary angiography, etc) will 
depend on the nature of the heart disease suspected or ascertained. 
In a good proportion of patients, this evaluation yields a definitive diagnosis of 
the cause of the symptoms, or at least excludes the presence of major arrhythmic 
disorders with reasonable certainty (3). However, the lack of an electrocardiographic 
recording during symptoms permits only a presuntive diagnosis (4). Thus, when the 
initial diagnostic evaluation results negative, and symptoms are clincal significant, 
(i.e. recurrent, poorly tolerated from the hemodynamic point of view, accompanied 
by reduction in quality of life and/or by traumatic injuries, or if the patient is suffer-
ing from heart disease), second-line diagnostic investigations, such as electophysi-
ological study (EPS), and prolonged ECG monitoring (AECG monitoring), should 
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be undertaken (1). 
Electrophysiological study. EPS, in addition to being costly 
and invasive, has a low sensitivity in the case of symptoms of 
unknown origin, at least in patients without significant heart 
disease (5-8). Moreover, EPS is a provocative tests, thus the 
correspondence between the induced arrhythmia and the 
arrhythmia responsible for the patient’s clinical symptoms is 
unproved. Indeed, EPS positivity only reveals the presence of 
a pathological substrate, which may (or may not) be responsible 
for the symptoms. It is therefore essential to establish the as-
sociation between the induced arrhythmia and reproduction 
of the patient’s spontaneous symptoms. Finally, the specificity 
and sensitivity of EPS depend on the  stimulation protocol 
employed, the type of induced arrhythmias, and the patients 
studied: its diagnostic value is higher in patients with structural 
heart disease, while aggressive protocols increase the sensitiv-
ity of the test at the expense of specificity. 
In patients with severe heart disease EPS should precede 
the use of AECG monitoring, while in all other cases, EPS is 
recommended only when AECG monitoring result negative. 
EPS does, however, offer the advantage not only of enabling 
the type of arrhythmia responsible for the symptoms to be 
correctly identified, but also of enabling ablation therapy of 
the arrhythmia itself (in case of induction of tachyarrhythmias) 
to be undertaken during the same session. 
Prolonged ambulatory ECG monitoring. Twelve-lead elec-
trocardiographic recording during the course of spontaneous 
symptoms constitutes the gold standard for the diagnostic 
evaluation of patients with symptoms of possible arrhythmic 
origin. Indeed, electrocardiographic recording is able to 
establish whether or not symptom are associated to a cardiac 
rhythm disorder and, in the majority of cases, leads to the cor-
rect diagnosis of the arrhythmia responsible (2,3). However, 
in normal clinical practice, it is not always possible to perform 
a standard 12-lead ECG  during spontaneous symptoms, and 
AECG monitoring is often necessary (-13). 
AECG monitoring devices (if we exclude the diagnostic 
funtions of pacemakers and ICDs) include the following: Hol-
ter monitoring, mobile cardiac outpatient telemetry (MCOT), 
event recorders, external loop recorders, and implantable 
loop recorders (ILR). Holter monitoring is  useful when 
symptoms have a daily frequency. Event recorders may prove 
useful in very compliant patients with infrequent symptoms 
that are fairly long-lasting to permit the activation of the 
device, and unaccompanied by hemodynamic impairment 
(such as syncope), that is likely to hinder their use. External 
loop recorders are recommended in cases of weekly symp-
toms, in very compliant patients, while ILRs  are indicated 
in poorly compliant patients with infrequent symptoms (i.e. 
with a monthly frequency) (14).
AECG monitoring is regarded as diagnostic only when it is 
possible to establish a certain correlation between symptoms 
and the electrocardiographic recording. Devices able to record 
arrhythmic events automatically (Holter and loop recorders) 
are regarded as probably diagnostic also if the patients will 
have evidence of asymptomatic sustained supraventricular 
or ventricular tachycardia, or significant bradyarrhythmias. 
Whenever it is possible to establish a relationship between 
patients symptoms and a ECG trace, the specificity of the 
test, at least to formulate the diagnosis of arrhythmic or non 
arrhythmic symptoms, is 100%. The sensitivity of the test, 
instead, is extremely variable, and depends upon the type of 
device employed, the duration of the monitoring period, the 
patient’s compliance, and the frequency of symptoms.
In patients with palpitations of unknown origin, Holter 
monitoring has been shown to have a rather low sensitivity 
(33 – 35%) (12). In a meta-analysis of 7 studies conducted in 
patients with syncope and/or palpitations of unknown origin, 
the sensitivity of Holter monitoring has been reported to be 
only 22% (13). External loop recorders have displayed a sensi-
tivity of 66- 73% in the study of palpitations of unknown origin 
(11). ILR devices have been used successfully in the study of 
syncope (15), in which they have shown a better cost/efficacy 
ratio than conventional tests, and recently, they also proved 
useful in the study of palpitations of unknown origin (16). 
The American FDA has approved the following indications 
for the use of ILRs: patients with clinical syndromes or situ-
ations at high risk of arrhythmia, and patients with transitory 
symptoms that may suggest a cardiac rhythm disorder. The 
European Society of Cadiology guidelines on management of 
syncope recommend the use of ILR in patients with syncope 
of possible arrhythmic origin, when all the other investigations 
result inconclusive. 
L O N G - t E r m  E v A L U A t I O N  O f  t O t A L 
( s Y m P t O m A t I c  A N D  A s Y m P t O m A t I c ) 
A r r H Y t H m I c  b U r D E N
First of all, we must remember that no recommendations 
exist in the literature  specifically regarding the use of AECG 
devices able to record arrhythmic events automatically. So 
we can olny hypotezise some possible indications for the 
new generation ILRs where  the long-term evaluation of the 
total (symptomatic and asymptomatic) arrhythmic burden 
of patients at risk of arrhythmic events may prove useful. 
Moreover, it must be underlined that the diagnostic value (i.e. 
sesitivity and specificity) of the present new generation ILR’s 
algorithms to automatically detect supraventricular and ven-
tricular tachyarrhythmic events are not yet definitively proved 
in clinical practice. So, all the followings are only hypothesis 
and they must be carefully verified and validated in clinical 
practice in the next future.
Silent atrial fibrillation. The algorhythms to automacally 
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detect arrhythmic events contained in the new generation 
ILRs may be useful for the long-term monitoring of patients 
with atrial fibrillation (AF). Indeed, success and efficacy of 
any AF treatment (drugs, ablation, etc.) is not easy to estab-
lish, because paroxysmal asymptomatic AF episodes are very 
frequent and carry the same clinical risks (such as tromboem-
bolic events and heart failure) of symptomatic events. Thus 
the symptom-based follow up tends generally to overestimate 
the success rate and the efficacy of therapy. Moreover, the 
symptom palpitation, which is frequently associated to an 
AF event, sometimes doesn’t correspond to this arrhythmia. 
Furthermore, the patient’s perception of AF may be change 
over time, especially after ablation. Therefore, the detection 
of both symptomatic and silent AF episodes results manda-
tory to verify the real success of any kind of treatment and to 
assess the need to continue anticoagulation therapy. In this 
setting, the new ILRs containing the algorithms to detect silent 
AF would probably be the optimal devices for the long-term 
monitoring of total AF burden of patients with previously 
documented paroxysmal/persistent AF, as well as of those 
at risk of developing AF, such as patients with cryptogenetic 
stroke, sleep apnea syndrome, chronic obstructive pulmonary 
disease, severe obesity, hypertension, and so on. 
Sudden death risk stratification. Another possible future 
indication of these devices could be the long term monitoring 
of patients at intemediate risk of ventricular tachyarrhythmias 
and sudden death. This could be the case of those patients 
with ischemic heart disease or dilated cardiomyopathy with 
only moderately depressed left ventricle ejection fraction, and 
those with arrhythmogenic heart disease, such as hypertrophic 
cardiomyopathy, arrhythmogenic right ventricular cardiomy-
opathy, Brugada syndrome, and Long QT syndrome, without 
clear indications to ICD implantation. Indeed, the long-term 
evaluation of ventricular tachyarrhythmic events by means of 
ILRs, could  permit a better prognostic stratification of the 
risk of sudden death in these patients.
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